Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells $119,145.06 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 4,887 shares of the stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $24.38, for a total transaction of $119,145.06. Following the completion of the sale, the chief technology officer directly owned 203,118 shares of the company’s stock, valued at approximately $4,952,016.84. This trade represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Tuesday, September 8th, Raymond Woo sold 4,887 shares of CeriBell stock. The stock was sold at an average price of $24.33, for a total transaction of $118,900.71.
• On Friday, August 21st, Raymond Woo sold 1,979 shares of CeriBell stock. The shares were sold at an average price of $24.02, for a total transaction of $47,535.58.

CeriBell Stock Performance

Shares of NASDAQ CBLL traded up $0.08 during mid-day trading on Friday, hitting $23.69. The company had a trading volume of 305,317 shares, compared to its average volume of 344,626. CeriBell, Inc. has a 12 month low of $10.85 and a 12 month high of $25.63. The firm has a market cap of $909.17 million, a P/E ratio of -13.46 and a beta of 0.94. The business’s 50-day simple moving average is $22.64 and its 200-day simple moving average is $20.21. The company has a debt-to-equity ratio of 0.16, a current ratio of 9.18 and a quick ratio of 8.79.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative net margin of 64.73% and a negative return on equity of 44.85%. The firm had revenue of $28.10 million during the quarter, compared to analyst estimates of $27.28 million. As a group, analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CBLL. TimesSquare Capital Management LLC acquired a new stake in CeriBell during the 2nd quarter valued at $15,182,000. Bank of New York Mellon Corp acquired a new position in CeriBell in the second quarter worth $17,437,000. BlackRock Inc. bought a new stake in shares of CeriBell during the second quarter worth $37,657,000. Deutsche Bank AG acquired a new stake in shares of CeriBell in the second quarter valued at $1,742,000. Finally, Landscape Capital Management L.L.C. acquired a new stake in shares of CeriBell in the second quarter valued at $2,078,000.

Analyst Ratings Changes

CBLL has been the topic of a number of recent research reports. Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. TD Cowen increased their price objective on shares of CeriBell from $29.00 to $33.00 and gave the company a “buy” rating in a research note on Friday. Canaccord Genuity Group raised their price objective on shares of CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Raymond James Financial reiterated a “strong-buy” rating and set a $29.00 target price on shares of CeriBell in a research report on Thursday, September 3rd. Finally, BTIG Research reissued a “buy” rating and issued a $30.00 target price on shares of CeriBell in a research note on Friday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CeriBell has a consensus rating of “Moderate Buy” and a consensus target price of $27.00.

CeriBell Company Profile

CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.

The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.